Conference
Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
Abstract
Background Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, has demonstrated efficacy and manageable safety in adult patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in the global, multicenter, pivotal, phase 2, JULIET trial (NCT02445248). The primary endpoint, overall response rate (ORR), was met at the interim analysis (ORR: 59% [CR, 43%; PR, 16%]). Here, we report an updated analysis with a …
Authors
Schuster SJ; Bishop MR; Tam CS; Borchmann P; Jaeger U; Waller EK; Holte H; McGuirk J; Jaglowski S; Tobinai K
Volume
25
Pagination
pp. s20-s21
Publisher
Elsevier
Publication Date
March 2019
DOI
10.1016/j.bbmt.2018.12.089
Conference proceedings
Transplantation and Cellular Therapy
Issue
3
ISSN
2666-6367